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Abstract
An underlying disease affecting bone health is present in up to 40 and 60% of osteoporotic postmenopausal women 
and men respectively. Among the disorders leading to a secondary form of osteoporosis, the endocrine diseases are 
highly represented. A frequent finding in patients affected with an endocrine-related forms of bone disease is that the 
skeletal fragility is partially independent of the bone density, since the fracture risk in these patients is related more 
to a reduction of bone quality than to a decrease of bone mass. As a consequence, bone mineral density evaluation 
by dual-X-ray absorptiometry may be inadequate for establishing the risk of fracture in the setting of the endocrine-
related forms of osteoporosis. In the recent years, several attempts to non-invasively estimating bone quality have 
been done. Nowadays, some new tools are available in the clinical practice for optimising the fracture risk estimation 
in patients with endocrine disorders. The aim of this review is to summarise the evidence regarding the role of the 
different imaging tools for evaluating bone density and bone quality in the most frequent forms of endocrine-related 
osteoporosis, such as obesity, diabetes, acromegaly, thyrotoxicosis, primary hyperparathyroidism, hypercortisolism 
and hypogonadism. For each of these disorders, data regarding both the current available tools and the future 
possible new techniques for assessing bone fragility in patients with endocrine diseases are reported.
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Osteoporosis is a skeletal disorder characterised by 
compromised bone strength predisposing a person to 
an increased risk of fracture (1). Bone strength primarily 
reflects the material composition and structural design of 
bone by the integration of bone mineral density (BMD) 
and bone quality (1). The latter concept mainly include 
bone geometry (bone size, shape), bono macro- and micro-
architecture (e.g. connectivity and thickness of trabeculae, 
thickness and porosity of cortical bone), the balance and 
rate of bone remodelling, bone mineralisation and the 
type and organisation of collagen or other components of 
the bone matrix.
Osteoporosis is classified as ‘primary’ when it occurs 
in the absence of an underlying disease and as ‘secondary’ 
when it is due to an underlying disease (2). It is known 
that up to 40% of postmenopausal women and 60% of 
men have factors contributing to osteoporosis when 
evaluated for underlying causes of the disease (2). Among 
the disorders leading to a secondary form of osteoporosis, 
the endocrine diseases are largely represented (2) and 
listed in Table 1. Patients affected with endocrine-related 
forms of osteoporosis frequently experience fragility 
fractures in the presence of a normal or slightly reduced 
BMD, since the fracture risk in these forms is related 
more to a reduction of bone quality than to a decrease 
of BMD (2). As a consequence, the BMD evaluation by, 
for example, dual-X-ray absorptiometry (DXA), which 
is of great importance in evaluating the fracture risk in 
primary osteoporosis (i.e. a T-score value ≤−2.5), may 
be inadequate for establishing the risk of fracture in the 
setting of the endocrine-related forms of osteoporosis.
In the recent years, several attempts to non-invasively 
estimating bone quality have been done. Nowadays, 
some new tools are available in the clinical practice 
for optimising the fracture risk estimation in patients 
with endocrine disorders affecting bone. The aim of 
this review is to summarise the evidences regarding the 
role of the different imaging tools for evaluating bone 
density and bone quality in the most frequent forms 
of endocrine-related osteoporosis. Although in studies 
examining secondary causes of osteoporosis, low vitamin 
D levels are consistently highlighted as the most common 
biochemical abnormality, we will not address this issue, 
since hypovitaminosis D is an important contributor to 
bone fragility, but it is not specific of a particular endocrine 
disorder influencing bone health. Finally, even though the 
mineralisation disorders may have an endocrine basis, we 
believed that addressing this issue was beyond the scope 
of the present review.
Obesity
Morbid adipose tissue accumulation may be regarded as a 
quite common disorder in a variety of endocrine diseases, 
although the factors accounting for the development 
of obesity in endocrinopathies have not been clearly 
identified. It is also well known that adipose tissue 
is regarded by now as an important endocrine organ 
since it produces several biologically active substances, 
for example, adipokines, with paracrine and endocrine 
action potentially leading to severe disorders of the 
endocrine system. Consequently, it is not far from the 
truth to consider obesity as an endocrine disorder more 
than a dysmetabolic condition. However, obesity has a 
complex and still poorly understood relationship to bone 
health. A fracture-related morbidity seems to be higher in 
obese than in non-obese women (3). It is also known that 
higher fat depots may have negative effects on bone, since 
both cytokines produced by visceral fat may exert a pro-
resorptive effect and high intramuscular fat accumulation 
is associated with poorer muscle function, attenuating 
loading effects and increasing falls risk, partly similar to 
what was observed also in T2DM (4). In a study published 
in 2000, the waist-hip ratio (WHR) index was associated 
with the risk of hip fracture (5), and later visceral adipose 
tissue (VAT) also was positively associated with nonspine 
fractures (6). A recent systematic review and meta-analysis 
of prospective studies reported that abdominal obesity 
was positively associated with the risk of hip fracture (7).
A direct positive correlation between BMI and BMD 
has been reported in the literature (8, 9). Thus, in the 
past years, obesity status was believed to be protective 
against fragility fractures. Lately, several studies argued 
that obesity, as defined by WHO criteria by the a BMI 
equal to or above 30 kg/m2, could no longer be regarded 
as a real protector from bone fragility. In fact, several 
Table 1 Main endocrine disorders associated with an 
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findings demonstrated that while on the one hand BMI is 
associated with increased risk of fracture at some skeletal 
sites, on the other hand, it may be protective at others 
skeletal sites, representing the so-called obesity paradox 
(8). Table  2 reports a summary concerning some of the 
factors, pros and cons, potentially associated in the 
interrelationship between obesity and bone mass.
DXA essentially focuses on the mineralised component, 
and it is still the most widely used tool to assess BMD to 
estimate the bone fragility fracture risk. In a study on 
obese patients, more than 50% of subjects, with at least 
one vertebral fracture, exhibited a normal or only slightly 
reduced BMD, but not osteoporosis, and vertebral fractures 
occurred 4.4-fold more frequently in patients than controls, 
thus suggesting that in obese population DXA may not 
represent an accurate instrument to adequately estimate 
the fracture risk (10). Data on the risk of hip fractures in 
obese patients are not conclusive even for the influence 
of diabetes (11). In fact, since obesity and excess fat mass, 
especially VAT, are increasing risk factors for low BMD and 
fragility fractures (3), in obese or overweight subjects the 
BMD measured by DXA may not be a reliable method 
of assessing fracture risk. Finally, by a practical point of 
view, in very obese patients, especially in whom the body 
weight exceeds the limit for the DXA table, the BMD 
assessment should be performed not only at the ‘classical’ 
lumbar and femoral sites, but also at the non-dominant 
forearm. In obese patients undergoing bariatric surgery or 
medical (diet) weight loss regimens with anticipated large 
weight loss, the DXA total body composition with regional 
analysis can be used in order to assess fat and lean mass 
changes when weight loss exceeds approximately 10%, 
but not for fracture risk assessment (12).
Recently, a dedicated algorithm for the assessment 
of bone microarchitecture at the lumbar spine (LS), the 
trabecular bone score (TBS), has been introduced. TBS 
is a textural index based on evaluating pixel grey-level 
variations in the LS DXA image, providing an indirect 
index of bone architecture. Thus, TBS can assess bone 
quality and provide information about fracture risk 
independent of BMD. Interestingly, BMD has been 
reported to correlate positively with BMI, whereas TBS has 
been described to be inversely related to BMI, suggesting 
that an increase in BMI has a negative impact on bone 
quality (13). Therefore, TBS seems to be a better measure 
of bone fragility in individuals who are obese/overweight 
and useful in assessing osteoporotic fracture risk, with 
lower TBS values associated with increased fracture risk. 
Lately, a prospective study on 38 morbidly obese white 
women, undergoing Roux-en-Y gastric bypass (RYGB) 
procedure, followed up to 3 years, demonstrated that the 
fracture risk, calculated by FRAX® algorithm (University 
of Sheffield, Sheffield, UK), with and without adjustment 
by TBS, was low, and the authors interestingly concluded 
that women undergoing RYGB in the mid-term have a 
preserved bone microarchitecture assessed by TBS (14). 
However, larger randomised prospective clinical trials 
will be necessary before suggesting TBS as a significant 
valuable technique for the prediction of fracture risk 
in obese subjects. A new tool to assess bone health, the 
BMD/BMI ratio has been recently presented, at the 27th 
American Association of Clinical Endocrinologists (AACE) 
meeting, held, on May 2018, in Boston, MA, US (https://
www.medscape.com/viewarticle/896882), by Watanabe 
and co-authors. They suggested such a simple measure 
as an important new tool to potentially and easily assess 
the risk fracture in obese patients, particularly when the 
bone strength could be linked to the presence of impaired 
metabolic health. They investigated a large Caucasian 
cohort of more than 2000 overweight or obese patients 
(82% female, aged 45 ± 12 years, mean BMI 36.5 ± 6.2 kg/
m2) by assessing the body composition, and both DXA 
LS BMD and TBS. Confirmation of the association 
between increased BMI, increased BMD and decreased 
TBS values has been obtained. The LS BMD/BMI ratio 
was more strongly correlated with TBS than LS BMD. In 
obese subjects with metabolic syndrome, the LS BMD 
was similar to that of metabolically healthy subjects, but 
both TBS and BMD/BMI ratio were significantly lower. 
All these preliminary findings suggest that the BMD/




 Increased androgen levels (women) 
 Conversion from androgen into oestrogen
 Increased levels of free sex hormones 
 Secretion of insulin and amylin by beta cells
 Increased glucagon-like peptide 2 
 Adipokines
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 Reduced insulin-related signalling (insulin resistance)
 Adipokines
 Hyperglycaemia in obese-T2DM subjects
 Inflammation and pro-inflammatory cytokines
 Dyslipidaemia
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BMI ratio offers a simple tool for assessing the risk of 
fracture in obese subjects (https://www.medscape.com/
viewarticle/896882). However, it will be necessary to 
wait for the effective publication of these data, and their 
possible replication in other studies.
As above suggested, obese patients may have 
normal DXA measured BMD values, despite of a possible 
deterioration in bone architecture and, consequently, 
an increased prevalence of vertebral fractures (13). The 
spinal deformity index (SDI) conjugates and integrates 
both the number and severity of vertebral fractures as 
a single parameter and it has been suggested to be an 
indirect surrogate marker of bone microarchitecture 
(15). According to this technique, fractures assessed on 
lateral thoracolumbarspine radiographs were defined 
as reductions of more than 20% in anterior, middle or 
posterior vertebral height. From lateral spine radiographs, 
each vertebra is visually assessed as intact (semi-
quantitative, SQ, grade 0) or as having approximately mild 
(20–25% compression), moderate (25–40% compression) 
or severe (>40% compression) deformity (SQ grades 1, 2 
and 3, respectively). Subsequently for each subject the SDI 
was calculated by summing the SQ grade for each of the 
13 vertebrae from T4 to L4. In a prospective study on 54 
obese subjects (51 ± 16 years, 10 males, 44 females), SDI 
was found to be an useful index of vertebral fractures 
risk, as it has been demonstrated in postmenopausal 
osteoporotic females (10).
Beyond the ‘classical’ thoraco-lumbar projection 
radiography, DXA scanners can also be utilised for 
vertebral fracture assessment (VFA) of a lateral image 
of T4 to L4 spine, with a significantly reduced dose 
than ‘classical’ X-rays and a high degree of accuracy in 
diagnosing fracture (16). This is of importance since the 
presence of a prevalent asymptomatic vertebral fractures 
is a strong predictor of future fractures (17). However, 
sometimes in large obese subjects, neither DXA nor the 
VFA can be performed because their weight exceeds the 
limit for DXA table, or the important thickness of VAT 
may alter the reliability of the result (12). Further imaging 
may be required where other underlying pathology 
is suspected and magnetic resonance imaging (MRI), 
computed tomography (CT) and nuclear medicine or 
positron emission tomography CT may be used.
Osteoporosis associates with an increased bone 
marrow fat (BMF) due to a shift in the differentiation 
pattern of mesenchymal stem cells that preferentially 
move more towards the adipocytes phenotype rather 
than to osteoblastic lineage (18). More recently, several 
studies have strongly evidenced the role that also 
non-mineralised bone component potentially play in 
determining bone health (18, 19). In particular, such 
studies stand that bone marrow, primarily consisting 
of adipocytes (yellow marrow areas) or adipocytes and 
haematopoietic red blood cells (red marrow areas), fills 
the cavities present at the trabecular bone level, and 
higher BMF fraction (BMFF) have been associated with 
lower BMD values (20, 21, 22, 23, 24, 25, 26). Moreover, 
in comparison to white and brown adipose tissue depots 
or ectopic fat depots in the human body, BMF exerts a 
distinctly different function, potentially playing an 
important role in the pathophysiology of metabolic 
disorders and fragility fracture risk (26). For these reasons, 
MRI and magnetic resonance spectroscopy (MRS) have 
been suggested as ideal imaging techniques for a non-
invasive investigation of BMF properties. However, MRI-
based evaluation of BMF may provide an interesting 
insight into the pathophysiology of osteoporosis and/or 
obesity, and it could be useful in the investigations on the 
association of bone and metabolic disturbances.
BMFF may represent a negative predictor of bone 
microarchitecture and mechanical properties in obese 
men, and it has been positively associated with ectopic 
and serum lipid levels in obese men and women and 
to their increase following a 6-month growth hormone 
administration in obese women (27). In a study on 47 
premenopausal women, the vertebral BMFF was positively 
associated with VAT and inversely associated with insulin-
like growth factor 1 (IGF-1), suggesting that VAT might 
have negative effects on bone health, partially mediated 
by IGF-1, a regulator of both fat and bone lineage (28). 
Changes of the BMF and bone mass after RYGB surgery 
have been investigated on 11 women, six diabetic and five 
non-diabetic, undergone RYGB, LS MRS, anthropometric 
measurements, whole body fat and BMD measurements. 
A positive correlation between age and BMF content 
was described, and, interestingly, mean BMF decreased 
in the diabetic subjects, versus non-diabetic women 
who showed only a small change, suggesting that BMF 
may behave differently than other fat depots in patients 
without diabetes after RYGB (24). However, further studies 
with larger number of specimens are needed in order 
to investigate whether the BMF has an effect on bone 
strength after correcting for the contribution of BMD. The 
currently available MRI-based methods, including MRS 
and water–fat imaging, enable the non-invasive extraction 
of the BMFF and unsaturation, but the knowledge of the 
underlying mechanisms is extremely scarce and, above all, 
no information is available in relation to their effective 
role in the clinical evaluation of fracture risk in subjects 
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with reduced bone mass; therefore, at the moment, their 
use is reserved only for research purposes.
Finally, an interesting review on bone health after 
bariatric surgery in obese patients evaluated also the bone 
mass technical approaches in this obese population and 
addressed the use of quantitative computed tomography 
(QCT)-based modalities to examine volumetric BMD 
and compartment-specific density and microstructure 
(29). Promising results come out, indicating that QCT 
technology can strengthen and advance the knowledge 
base. In particular, a pronounced reduction of bone 
mass at appendicular skeleton has been demonstrated by 
high-resolution (HR) peripheral quantitative computed 
tomography (pQCT, HR-pQCT), evaluating volume BMD 
(vBMD), other than in bone mass at the axial skeleton 
as assessed by DXA and QCT (30, 31, 32, 33), even if it 
has been reported that HR-pQCT underestimates vBMD 
decrease when performed on important reduction in fat. 
(32). HR-pQCT studies seem also to adequately provide 
an individual analysis at both cortical and trabecular 
compartments, allowing for the identification of distinct 
pattern of bone loss. In fact, some studies revealed that 
the decrease in total vBMD, at the radius level, mainly 
reside in decreasing of trabecular vBMD, whereas the 
tibial total vBMD mainly reduces either within the cortical 
compartment or within both trabecular and cortical 
compartments (31, 32, 33). By this approach, information 
on bone microstructure and estimated strength at the 
appendicular skeleton can also be extrapolated (30, 31, 32, 
33, 34, 35). In obese bariatric subjects, undergoing different 
surgical approach, the HR-pQCT analysis provided a 
quantitative characterisation of bone microstructure 
at compartmental level, documenting deterioration in 
either trabecular or cortical architecture (30, 31, 32): (i) a 
decrease of trabecular number and trabecular separation 
within the trabecular bone, with consequent increased 
heterogeneity (31, 32, 33); (ii) a decrease of the cortical 
thickness and an increase of the trabecular area, due to 
endocortical resorption (26, 27, 28); (iii) a pronounced 
increase of cortical porosity (31, 32, 33). All these findings 
suggest also reduction of the bone strength at both the 
radius and the tibia (31, 32) with the consequent increase 
in fracture risk.
Diabetes
Emerging evidence suggests that diabetes exacerbates age-
related reductions in bone strength and quality leading 
to increased bone fragility (36). In fact, type 1 diabetes 
(T1D) is associated with four- to six-fold increased risk of 
fractures that begins in childhood and extends across the 
life span. Likewise, a similar, albeit less marked, increase 
in the prevalence of fragility fractures has also been 
described in type 2 diabetes (T2D), particularly affecting 
the hip and other peripheral skeletal sites (37). While in 
T1D patients a modest decrease in BMD at trabecular and 
cortical sites is generally described, in T2D patients normal 
or even higher than normal BMD levels are frequently 
observed (37). Collectively, these findings indicate that 
BMD measurement does not consistently account for 
the increase in bone fragility in diabetes and suggest that 
abnormalities in bone microarchitecture and/or material 
composition (not captured by DXA) are likely responsible 
for the observed increase in fracture risk in either T1D and 
T2D diabetic patients.
The mechanisms underlying bone fragility in diabetes 
have not been clearly established and might differ, at least 
in part, between T1D and T2D, due to differences in the 
onset of disease, in insulin concentrations and resistance, 
as well as in the therapeutic approaches (36, 38). Common 
mechanisms might include co-morbidities and increased 
risk of falls associated with diabetes or direct effects of 
hyperglycemia on the skeleton such as a suppression of 
bone turnover and excessive accumulation of advanced 
glycation end products on collagen fibrils, which have an 
impact on bone quality and strength (36).
Based on the above considerations, the stratification 
of fracture risk in diabetes, particularly in T2D patients, 
cannot exclusively rely on the DXA measurement of BMD 
(either alone or in combination with the conventional 
risk factors for fracture) as it occurs in postmenopausal 
osteoporosis (39). Likewise, the algorithms such as FRAX, 
the WHO Fracture Risk Assessment Tool, underestimate 
fracture risk in T2D patients (31, 40). Obviously, the 
finding of a low BMD still remains predictive of bone 
fragility in diabetic patients, as in the general population, 
and thus, has to be considered useful for estimating 
the fracture risk (39). In fact, for each 1 SD decrease in 
BMD, the risk of hip fracture is almost equally doubled in 
individuals with or without T2D (35). However diabetic 
patients generally have fractures at higher BMD levels 
than the general population, with T-score levels often 
above the osteoporotic range. Thus, concerning T2D, it 
has been estimated that a similar increase in hip fracture 
risk than in non-diabetic subjects occurs at 0.6 SD and 0.4 
SD higher BMD levels in women and men, respectively 
(40). In addition to BMD measurement, a spinal X-ray 
should be mandatory in diabetic patients with a previous 
fragility fracture or in those with diabetic complications, 
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particularly in the presence of a poorly controlled disease. 
Indeed, when investigated by a lateral spine radiograph, 
up to a third of postmenopausal T2D women showed 
asymptomatic, morphometric, vertebral fractures (42), 
that per se represent a major risk factor for subsequent 
fractures (43).
As a consequence of the difficulties of relying on 
BMD to assess fracture risk in diabetes, other imaging 
techniques have been investigated in the past few years 
to better understand the mechanisms of skeletal fragility 
in either T1D or T2D (44), as summarised in Table  3. 
Different cross-sectional and retrospective reports have 
suggested that TBS is often reduced in either T1D or T2D 
(44) and that might predict fracture risk better than BMD 
(44, 45, 46).
The hip structural analysis (HSA) represents an 
additional tool that can be applied to DXA in order to obtain 
information on bone geometry and indirectly assess the 
bone resistance to axial compressive forces (47). However, 
although a weaker geometry (e.g. a narrower neck width) 
and compromised estimates of skeletal load response (e.g. 
a lower buckling ratio) have been described using HSA 
in some cohorts of T2D patients (47), their additive role 
on the prediction of fractures remains to be established. 
Notwithstanding the low cost and the wide availability of 
quantitative ultrasound (QUS) devices of the calcaneous 
and the phalanxes, limited information has been released 
about their use in diabetic patients. Available information 
from cross-sectional studies indicate that QUS parameters 
may be reduced in patients with either T1D or T2D (48), 
but conflicting data exist concerning their predictive role 
in discriminating patients with fragility fractures (48, 49). 
Moreover, a correlation between reduced QUS parameters 
and poor glyco-metabolic control or peripheral nerve 
dysfunction was also described (50).
Recently, QCT and HR-pQCT of the distal radius and 
tibia have been employed to obtain a 3D assessment of 
bone size, vBMD, bone macro- and microarchitecture 
(e.g., cortical porosity and trabecular connectivity). The 
use of these techniques indicated that T1D patients are at 
risk for smaller sizes of the appendicular bones at the end 
of pubertal growth and generally shows thinner cortices as 
well as thinner and more widely spaced trabeculae (44, 51). 
These structural bone deficit appears more pronounced in 
the presence of microvascular complications (52). Similar 
studies in T2D patients have demonstrated preserved 
indices of trabecular microarchitecture but increased 
cortical porosity, particularly in T2D females with fragility 
fractures (53, 54, 55, 56).
Very limited information is available concerning 
the use of MRI to assess trabecular and cortical bone 
parameters at both axial and peripheral skeleton and their 
role in the stratification of fracture risk in diabetic patients 
(25). Notably MRS of the vertebral bodies evidenced an 
altered BMF composition (with lower unsaturation of bone 
marrow lipids) in postmenopausal women with fragility 
fractures and T2D (21). This approach might represent 
a promising tool for fracture risk assessment in diabetes, 
given the negative role of BMF on the commitment of 
mesenchymal stem cells towards the osteoblast lineage 
and its detrimental implications one BMD and structural 
bone integrity (18, 25, 26).
However, despite the promising results from 
retrospective and cross-sectional observations and the 
Table 3 Fragility fracture risk and most frequent findings in the evaluation of bone mineral density and bone quality in the 
endocrine-related forms of osteoporosis.
Disorder VFx risk Hip Fx risk DXA TBS Available data from other imaging tools 
Obesity ↑ N.A. N/High Reduced MRS for BMF estimates
Type 2 diabetes ↑ ↑ N/High Reduced QUS, HSA, QUS, QCT, HR-pQCT, MRI, MRS for BMF estimates
Type 1 diabetes ↑↑ ↑↑↑ ↓↓ Reduced QUS, QCT, HR-pQCT
Acromegaly ↑↑ N.A. N Reduced HR-pQCT
Overt hyperthyroidism ↑ ↑ ↓↓ NA NA
Subclinical Hyperthyroidism ↑* ↑ ↓↓ Reduced QCT, HR-pQCT, HAS
Primary Hyperparathyroidism ↑ ↑ ↓ Reduced QUS
Overt Hypercortisolism ↑↑↑ ↑ ↓↓ Reduced QUS, QCT
Subclinical hypercortisolism ↑↑ N.A. ↓/N Reduced QUS, QCT
Hypogonadism in CTIBL ↑↑ ↑↑ ↓/N Reduced MRI, QCT, MDCT
*In postmenopausal women.
↑ up to two-fold increased; ↑↑ 2–5 fold increased; ↑↑↑ more than five-fold increased; ↓↓ severely reduced (i.e. T-score ≤−2.5); ↓ reduced (i.e. T-score 
between −1.0 and −2.5); N, normal (T-score >−1.0); BMF, bone marrow fat; CTIBL, cancer treatment-induced bone loss; HAS, hip structural analysis; 
HR-pQCT, high-resolution peripheral QCT; MDCT: multidetector-row computed tomography; MRI, magnetic resonance imaging; MRS, magnetic resonance 
spectroscopy; N.A., data not available; QCT, quantitative computed tomography; QUS, quantitative ultrasound.
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positive indications from experimental studies, the 
clinical relevance of imaging techniques other than DXA 
and vertebral morphometry for the prediction of fracture 
risk in patients with diabetes needs to be confirmed on 
a prospective basis and their scarce availability and high 
cost do not consent their routine use.
Acromegaly
Bone cells represent a target for the growth hormone (GH) 
and for its mediator, the insulin-like growth factor 1 (IGF-
1). These hormones mainly act on osteoblasts by inducing 
their differentiation and by enhancing their function. To 
a lesser extent IGF-1 may also activate osteoclasts through 
an increase of RANKL production. Pituitary adenomas 
overproducing GH cause acromegaly, a disease that induces 
bone enlargement, particularly in extremities (57). Until 
recent years, acromegalic patients have been considered as 
having high bone mass, but in the last decade a large body 
of evidence have emerged as to the presence of fragility 
fractures in people with acromegaly (57).
The attempt to measure BMD by means of a 
traditional method like DXA has given inadequate results 
in acromegaly. Importantly, spine BMD is usually normal 
in this disease, while hip BMD may even be higher than 
normal (57).
Notwithstanding the high bone mass acromegalic 
patients show an up to eight-fold increased rate of 
vertebral fragility fractures that may be explained by a 
reduction of bone quality rather than bone quantity. An 
increased cortical thickness and porosity and a reduced 
trabecular thickness with increased trabecular separation 
have been demonstrated in acromegalic patients (58); 
therefore, it is reasonable that other methods possibly 
measuring bone quality have been studied. Recently, two 
recent papers focused on the role of TBS in acromegaly. 
Hong and co-authors found lower values of TBS in 
acromegalic men and women than in matched controls, 
while no difference in BMD has been observed between 
the two groups (59). The second study demonstrated that 
acromegaly treatment increases BMD but contemporarily 
reduces TBS by 3% in both genders, with males tending to 
a more pronounced, but not significantly different, TBS 
decrease than females (60).
Another method that is used to measure bone 
quality is HR-pQCT, which by analysing the distal radius 
and tibia allows the in vivo assessment of both bone 
microarchitecture and volumetric BMD. Using HR-pQCT 
in 82 patients with acromegaly, Madeira et al. have found a 
severe deterioration of trabecular bone microarchitecture 
that was correlated with patients’ gonadal status rather 
than with the presence of type 2 diabetes or the activity 
of the disease. Therefore, a sub-analysis was performed 
on 45 eugonadal acromegalic patients compared with 45 
healthy controls. The patients showed lower trabecular 
volumetric bone density, bone volume to tissue volume 
and trabecular number than controls. Moreover they had 
higher trabecular separation and spacing than healthy 
subjects (61). All these findings can be associated with 
greater bone fragility, that, as previously demonstrated, is 
increased by hypogonadism (62).
Although eugonadal acromegalic patients show better 
bone quality than hypogonadal ones, a deterioration 
in trabecular microstructure of the radius has been 
demonstrated also in males with normal testosterone 
suggesting that acromegaly may overwhelm the protective 
role of sex steroids (63).
Also cortical bone is altered in acromegaly as both 
increased cortical porosity and reduced cortical strength 
have been demonstrated by several papers (58, 60, 63). A 
recent paper evaluated trabecular and cortical parameters 
at distal radius level, by means of a HR-pQCT system, 
in 40 acromegalic patients and 21 healthy subjects (65). 
Patients with acromegaly showed lower bone volume/
trabecular volume (BV/TV) ratio and mean trabecular 
thickness as well as a greater trabecular separation than 
controls, but no difference between the two groups was 
observed with regard to cortical thickness and porosity. 
As compared to acromegalic patients without vertebral 
fractures, acromegalic patients with vertebral fractures 
showed lower BV/TV ratio and both greater trabecular 
separation and higher cortical porosity, but they did 
not differ in terms of cortical thickness and porosity 
(65). These results are very interesting as they show an 
increase of both cortical area and thickness together with 
a higher cortical porosity, reflecting a normal response to 
the enhanced bone turnover induced by GH and IGF-1 
excess. Generally the increase of cortical pores reduces 
the resistance to mechanic loads, but in this very case, 
the simultaneous cortical bone enlargement seems to 
counteract the reduction of bone stiffness. The authors 
hypothesise that the difference in trabecular and cortical 
bone response to enhanced turnover may account for the 
described difference in fracture occurrence in acromegaly 
(i.e. increased risk for vertebral, but not appendicular 
fractures) (66). In contrast with these results a recent 
paper by Malgo et  al. has investigated cortical strength 
by means of microndentation, a novel technique that 
allows the in vivo measuring of the so-called ‘Bone 
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Material Strength Index (BMSi)’ (64). Patients with well-
controlled acromegaly showed significantly lower BMSi 
values than healthy controls These results seem to suggest 
a reduced cortical bone strength in acromegaly that may 
be a reflection of persistent alterations in the material 
properties of cortical bone even after cessation of the 
disease (64).
In conclusion, a growing body of evidence in the last 
10–15  years have shown an increased rate of fractures 
in acromegaly, particularly at the vertebral level, that 
are strictly correlated with a deterioration of bone 
microstructure caused by GH and IGF-1 overproduction. 
DXA is the most efficient way to measure bone mineral 
density in the general population and it show a very good 
correlation with fracture risk; nevertheless its efficacy in 
acromegaly is poor as BMD is generally normal in this 
disease, particularly at the hip level. Therefore as we have 
learned with other diseases, like glucocorticoid-induced or 
T2D osteoporosis, DXA does not represent a valid tool for 
fracture risk estimation in acromegaly. Promising results 
are coming from the few studies on TBS, on HR-pQCT 
or on microindentation as all these methods seem to be 
able to estimate bone quality. In particular, pQCT may 
represent a new method for discriminating acromegalic 
patients with vertebral fractures and it is a good prospect 
for predicting fracture occurrence in acromegaly. Further 
studies are necessary in order both to confirm these data 
and to test new methods for the assessment of bone 
quality in acromegaly.
Thyrotoxicosis
Thyroid hormones have important effects on skeletal 
development, linear growth and the maintenance of adult 
bone mass and strength. Thyroid gland mainly secrets 
thyroxine (T4) that is consequently metabolised in the 
active hormone 3,4,3′-L-triiodothyronine that enters the 
cellular nucleus where activates thyroid hormone receptor 
α or β (TRα, TRβ). TRβ is the main receptor expressed 
in the hypothalamus and pituitary where it mediates 
negative feedback control, regulating thyroid-stimulating 
hormone (TSH) secretion, while TRα is the main receptor 
expressed in the skeleton. During childhood thyroid 
hormones accelerates skeletal development and bone 
maturation. Indeed, almost all pre-pubertal children with 
thyroid hormone excess have tall stature at diagnosis, 
with a height SD score significantly greater than that of 
their parents. However, this accelerated bone maturation, 
with a premature fusion of the growth plate, may lead 
to an adult short stature. In the adults, thyroid hormone 
stimulate bone turnover via increased osteoclastic 
bone reabsorption (67). The thyroid hormones excess 
causes a reversible bone loss due to an expansion of 
the re-modelling space and an irreversible loss due to a 
negative net bone balance and eventually an increased 
risk of trabecular perforations (68, 69).
Overt hyperthyroidism is a well-established cause of 
high bone turnover osteoporosis, resulting in an increased 
susceptibility to fracture. However, even subclinical 
hyperthyroidism, both endogenous and exogenous (i.e. 
TSH-suppressive therapy), which is characterised by 
normal thyroid hormones level and suppressed TSH, 
seems to be associated with an increased risk of fracture. 
TSH receptor is expressed also in chondrocytes, osteoblasts 
and osteoclasts and TSH is thought to exert a positive 
direct effect in bone metabolism (68).
The effects of overt hyperthyroidism on bone 
mineralisation have widely been documented by DXA. A 
decrease in BMD is present at all skeletal sites, including 
spine, femur, radius and total body, and it is greater in 
postmenopausal women. The close relationship between 
observed and BMD-estimated fracture risk could indicate 
that most of the changes in fracture risk are related 
to changes in BMD, and that other factors, such as an 
increased risk of falls, play a minor role (69). However, 
importantly, in the meta-analysis of a Vestergaard 
and co-authors, the increased risk of hip fracture was 
independent of hip BMD (69). Thus, in the condition of 
thyroid hormone excess, components of bone fragility 
that are entirely independent of conventional BMD may 
be present.
After a diagnosis of hyperthyroidism is made and after 
at least 1 year of treatment with anti-thyroid drugs BMD 
increases and returns in the normal range for age and sex 
within 5 years; in parallel, the fracture risk, which is two- 
to three-fold increased at both femur and spine in patients 
with overt hyperthyroidism, returns to normal after 1 year of 
treatment, even without specific anti-osteoporotic therapy 
(69). Interestingly, BMD increases above the expected from 
1 to 4 years after diagnosis of hyperthyroidism. This may 
be explained by the idea that the normalisation of thyroid 
hormone levels induces a decrease in remodelling activity 
to subnormal levels and, consequently, a reduction in the 
remodelling space in this period. Following a lag time of 
5 years or more, normal bone turnover will resume again, 
expanding the remodelling space to normal size and 
resulting in normal BMD levels (69).
As observed in overt hyperthyroidism, postmeno-
pausal women with subclinical hyperthyroidism show 
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reduced BMD evaluated by DXA, while data in men and 
premenopausal women are more controversial. A recent 
paper shows that the annualised rate of bone loss at hip 
is increased two- or three-fold in individuals with sub-
clinical hyperthyroidism, especially in those with TSH 
below 0.10 mIU/L and high‐normal free thyroxine levels 
(70). In keeping, recent data show that subclinical hyper-
thyroidism is associated with an increased risk for hip 
and other fractures, with the highest risks in individuals 
with suppressed TSH (below 0.10 mIU/L), in those with 
endogenous subclinical hyperthyroidism and in patients 
above 60 years of age (71).
Nevertheless, in subclinical hyperthyroidism, DXA 
may not represent the best tool to detect bone damages 
and fracture risk, as in subclinical hyperthyroidism a 
reduction of bone quality may play an important role 
in determining the increased fracture risk. Indeed, 
in postmenopausal women treated with suppressive 
l-thyroxine doses, duration of TSH suppression was 
negatively correlated with TBS levels, but not with BMD 
(72). In keeping, vBMD obtained by central QCT showed 
a more significant correlation with TBS than areal BMD 
measured by DXA in these patients (73). Similarly, in 
postmenopausal women treated with TSH-suppressive 
therapy pQCT showed a significant trabecular bone loss, 
mainly at non-weight-bearing sites such as the radius (74). 
Moreover, pQCT did not show differences in terms of 
vBMD between patients and controls, in premenopausal 
women, but significant differences were observed in 
postmenopausal ones. Interestingly, in premenopausal 
women treated with TSH-suppressive l-thyroxine doses 
cortical thickness was higher at the radius compared 
with controls. At variance, in postmenopausal women at 
radius trabecular bone mineral content, area and vBMD 
and cortical thickness were reduced (74). Therefore, 
thyroid hormones excess seems to be associated with a 
reduction of both cortical and trabecular bone, but only 
in postmenopausal females.
In addition, the analysis of geometric bone structure 
properties using HSA showed that in postmenopausal 
women subclinical hyperthyroidism was associated with 
a decreased bone strength due to an alteration of bone 
geometry rather than BMD in the hip area, especially at 
the femoral neck (75).
In terms of fractures, several studies and meta-
analyses have reported an association between subclinical 
thyroid hormone excess and risk of clinical fractures, 
mainly in postmenopausal women (71, 76). A recent 
paper showed that about one-third of women treated with 
TSH-suppressive therapy present at least one vertebral 
fracture, evaluated by morphometric analysis (77). The 
presence of vertebral fractures correlated with duration of 
TSH-suppressive therapy, degree of TSH suppression and 
age. Interestingly, vertebral fractures were found even in 
patients with normal BMD, mainly when the TSH level 
was below 0.5 mU/L.
In conclusion, overt hyperthyroidism is associated 
with an increased fracture risk in both sexes, which is 
related to changes in BMD and at least partially reversible 
using treatment with anti-thyroid drugs. Subclinical 
hyperthyroidism, both endogenous and exogenous is 
associated with a higher fracture risk in postmenopausal 
women, while in premenopausal women and men its 
possible negative effects remain unclear. In patients with 
overt hyperthyroidism, DXA may represent a suitable 
tool to estimate fracture risk. Differently, in subclinical 
hyperthyroidism BMD changes are not well related 
with fracture risk, likely due to an impairment of bone 
quality. In subclinical hyperthyroidism, TBS evaluation 
may represent a useful and almost easy reachable tool to 
improve detection of higher risk patients. However, the 
clinical usefulness of TBS, QCT, pQCT and HAS for the 
prediction of fracture risk in patients with subclinical 
hyperthyroidism is still to be demonstrated. Anyway, 
a vertebral morphometry should be performed in 
postmenopausal women with subclinical hyperthyroidism; 
in addition, in patients treated with long-term TSH-
suppressive therapy a vertebral morphometry should be 
repeated during follow-up.
Primary hyperparathyroidism
In western countries the clinical picture of primary 
hyperparathyroidism (PHPT) with the devastating effect 
of very high levels of PTH on bone (i.e. osteitis fibrosa 
cystica) has become uncommon in the last decades, 
while the reduction of bone mass and the increased risk 
of fractures is part of the picture of the commonest mild 
PHPT. The effects due to the high rate of bone remodelling 
are well evident at cortical sites. Indeed, the cortical bone 
is more affected than the trabecular one. In the early 
70s, by using old methods, such as metacarpal index, a 
cortical thinning has been showed in PHPT patients. 
Since the amount of cortical and trabecular bone varies 
among different skeletal sites, the common techniques 
for evaluating bone mass are influenced by the site of 
measurement. Indeed, bone mass measurement by DXA 
shows the greatest reduction in BMD at mid- radius, 
the site of predominantly cortical bone, while at LS, a 
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site of predominantly cancellous bone, bone mass can 
be relatively preserved. At femoral neck a site of mixed 
composition, BMD is of intermediate value (78). These 
data have been confirmed by histomorphometric and 
microcomputed tomography (microCT) studies focused 
on cohorts of mild PHPT that showed cortical thinning, 
increased cortical porosity and endocortical trabeculation, 
but preservation of cancellous bone volume, bone surface 
and connectivity density of trabecular plates as compared 
to controls, independent of advancing age (79). These 
findings suggest that three-dimensional, cancellous bone 
microarchitecture is preserved in patients with mild PHPT 
(79). The conservatively follow-up of mild PHPT patients 
has shown over time a reduction of BMD as evaluated by 
DXA more evident at sites with prevalent cortical bone, 
while the surgical treatment, also in mild PHPT, results 
in increase of BMD by DXA at the distal third radius, 
femoral neck as well as LS (80). Consequently, BMD 
evaluation by DXA is mandatory at diagnosis of PHPT 
and in the follow-up. The risk of fractures (both at spine 
and femur) is about two fold increased in PHPT and it is 
reduced by parathyroidectomy (81). Furthermore, in mild 
PHPT, due to the preservation of trabecular bone, one 
should not observe any increase of vertebral fractures. 
In fact, in mild PHPT a higher risk of vertebral fractures 
was observed, although spine BMD was higher than in 
controls, thus suggesting that BMD does not seem to be 
the only factor determining fracture risk in mild PHPT 
(73), while the impairment of bone microarchitecture and 
quality (partially evaluated by TBS, HR-pQCT, QUS) could 
also explain the high risk of fractures. The same results 
were reported by a subsequent study (82), in which VFA 
by DXA was utilised for identifying fractures. In this study 
the accuracy of VFA compared with X-ray was 92% and 
sensitivity and specificity of VFA were 82.4% and 97.0%, 
respectively. According to the lower mineralisation in 
PHPT, some phalangeal ultrasound parameters are lower 
in PHPT than in controls. Phalangeal QUS, seems to 
evaluate structural characteristics of bone, rather than 
the mineral content and some QUS parameters would 
distinguish male and female postmenopausal patients 
with PHPT from normal controls, but not premenopausal 
patients (83). However, QUS is not commonly utilised for 
the characterisation of PHPT patients.
Recent studies showed that TBS appears to be more 
accurate than spinal BMD for identifying PHPT patients 
at risk for vertebral fractures (84). Other authors showed 
that TBS was associated with vertebral fractures regardless 
of BMD measured at spine, and had a better compromise 
between sensitivity (75%) and specificity (61.5%) for 
detecting fractured patients than spinal BMD. In surgically 
treated patients, TBS and spinal BMD increased over time, 
while in conservatively followed patients, TBS decreased 
significantly in those with incident vertebral fractures 
compared with those without, while spinal BMD did not 
significantly change (85).
By using HR-pQCT in PHPT patients, some authors 
reported decreased volumetric densities, thinner cortices, 
and more spaced and not homogeneously distributed 
trabeculae at trabecular and cortical compartments of 
distal radius and tibia (86). The individual trabecular 
segmentation (ITS) analysis of radius, derived from 
HR-pQCT images, showed reductions in both plate and 
rod trabecular numbers with plate indexes more affected 
in respect to controls. At the tibia, the ITS analysis showed 
that the plate trabecular number and plate bone volume 
were reduced. A reduction in the plate:rod ratio by 22% 
at the radius and 19% at the tibia, respectively, was 
observed. Data obtained by HR-pQCT showed that post 
parathyroidectomy, volumetric BMD, microarchitectural 
indices and estimated bone strengths improve (86).
Hypercortisolism
Cushing’s syndrome (CS) is a condition characterised by a 
large group of signs and symptoms that reflect prolonged 
tissue exposure to glucocorticoid excess of endogenous or 
exogenous origin. Endogenous cortisol overproduction by 
the adrenal glands can be due to either adrenocorticotropic 
hormone excessive secretion (from a pituitary or other 
ectopic tumour) or autonomous adrenal hyperfunction. 
Hypercortisolism is a well-known cause of endocrine-
related osteoporosis due to the detrimental effects on 
bone of cortisol excess, which produces an imbalance 
between bone resorption (normal or increased, especially 
in the early phase) and bone formation (impaired, 
particularly in the chronic phase). This alteration of 
bone turnover is one of the main mechanisms which 
leads to bone loss in CS. Many studies investigating bone 
density in CS patients demonstrated a reduced BMD in 
these patients (87). Areal BMD, as measured by DXA, was 
found to be significantly lower in patients with CS than 
in healthy controls at both the spine and the hip (88) and 
this reduction was confirmed even after the exclusion of 
hypogonadal subjects (88, 89), thus suggesting that the 
deleterious effects of hypercortisolism on bone overcome 
the protective effect of eugonadism in CS. The prevalence 
of osteoporosis in CS patients varies across studies and can 
be estimated between 30 and 70% (88, 89).
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The assessment of volumetric BMD, as measured by 
HR-QCT suggests that the cortisol excess affects more 
severely trabecular than cortical bone (87), even though 
some studies were not able to find this difference between 
these compartments. However, also the microarchitecture 
of cortical bone is probably injured in CS with lower 
cortical area and cortical thickness at both the radius and 
the tibia (88). In a study performed by QCT and pQCT, 
trabecular, but not cortical and integrated BMD, was 
significantly reduced in CS patients, suggesting different 
sensitivities of the two bone tissues to glucocorticoid 
excess at the forearm (89). In contrast to what observed 
at the forearm, both trabecular and cortical bone were 
similarly reduced in CS patients, indicating, therefore, 
that the different sensitivities to glucocorticoid excess 
of the two different bone tissues are site specific (i.e. 
present at the forearm but not at the femur). In addition, 
by comparing the BMD values for all affected sites in CS 
patients, spinal trabecular bone, as studied by QCT, was 
the most severely affected (89).
Data on bone density in CS as assessed by QUS are 
scarce and quite discordant. Few studies found a reduction 
of QUS parameters at the phalanges of the non-dominant 
hand (90) and at the heel (91) in CS patients, whereas 
others were not able to find any significant bone loss as 
measured by QUS (92).
However, the bone loss, independent of the technique 
used for the BMD measurement, does not fully explain the 
high fracture risk observed in CS. Indeed, approximately 
30-67% of CS patients experienced a clinical fragility 
fracture in the course of the disease, more commonly 
at the vertebral level (87) and, as demonstrated by 
Tauchmanovà and colleagues, this remarkable prevalence 
of fragility fractures appears to be underestimated, since 
in about a half of cases vertebral fractures are absolutely 
asymptomatic. Moreover, in about 10% of CS patients 
vertebral fractures occur in the presence of normal BMD 
(86), thus underlying the crucial role of the radiologic 
evaluation of the thoracic and LS, regardless of BMD, for 
the detection of vertebral morphometric fractures. As a 
consequence SDI has been proposed as a surrogate marker 
of bone microarchitecture even in CS (15, 93).
Indeed, the partial discrepancy between bone mass 
and fracture risk in CS can be explained by a damage of 
bone quality other than bone quantity caused by cortisol 
excess in CS patients. In addition to SDI, TBS has been 
proposed as another non-invasive technique able to give 
information on bone microarchitecture. Patients with CS 
exhibited low TBS values which inversely correlated with 
the degree of hypercortisolism and which improved more 
markedly and quickly than BMD after CS remission (94).
A recent work of Maurice and collaborators 
measured BMF content in CS patients by using MRS, 
which is considered the best available method for BMF 
quantification. They found that CS patients had increased 
BMF content compared to cured patients and healthy 
subjects (95). However further studies are required in 
order to clarify the precise link between BMF and bone 
microarchitecture in hypercortisolism.
It is worthy of attention how imaging evaluation 
can define skeletal fragility in patients with subclinical 
hypercortisolism (SH), which is a condition of cortisol 
excess in the absence of its classical signs and symptoms 
(96). As CS, even SH was demonstrated to be detrimental 
for the bone health, and most studies found a reduction 
in spinal BMD, as measured by DXA or QCT, in SH 
patients. At variance, data on femoral BMD in SH are 
more discordant (96). However, as compared with CS 
patients, in SH patients the degree of BMD loss is even 
less predictive of the risk of fracture, which is surprisingly 
comparable with that of CS patients, especially at the 
vertebral level. This is probably due to a longer exposition 
to cortisol excess in SH than in CS due to the absence 
of clinical signs and symptoms (96). As in patients with 
overt cortisol excess, in SH an alteration of the bone 
quality, rather than of bone quantity, is suspected to be 
the main responsible of the skeletal fragility (92) and TBS 
was found to be reduced in SH patients and correlated 
with the number and severity of vertebral fractures and 
with the degree of cortisol excess (97).
Hypogonadism
Bone health is a major concern in patients with 
hypogonadism. Oestrogen levels lower than 20 pg/
mL are associated with significant bone loss and levels 
below 5 pg/ml are associated with a 2.5-fold increase in 
hip and vertebral fractures independently of sex, age 
and body weight (98). In male hypogonadism, the BMD 
values associated to fracture risk are not so well defined 
as in postmenopausal women or glucocorticoid-induced 
osteoporosis. In hypogonadism the rate of bone loss 
is increased due to a very high bone turnover. This, in 
turn, decreases bone quality and increases the fracture 
risk partially independently of BMD reduction (99). 
Indeed, a high bone turnover impairs bone strength 
in excess that expected from the change in bone mass. 
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All acquired hypogonadisms, in particular in young 
age or if occur quickly (i.e. surgical or pharmacological 
castration) are associated with a very high bone turnover. 
The hormonal ablation for cancer adjuvant therapy 
or for endometriosis is the best studied secondary 
osteoporosis due to hypogonadism. Gonadotrophin-
releasing hormone agonists or analogues are used in 
prostate cancer, premenopausal breast cancer women 
and endometriosis. Furthermore aromatase inhibitors 
nowadays are the standard of adjuvant therapy in 
oestrogen receptor positive postmenopausal breast cancer 
(100). Bone loss in these patients, begin early after the 
beginning of hormonal therapy and progresses with high 
rate (100).
There are strong evidences that in the cancer treatment-
induced bone loss (CTIBL) as well as young women with 
endometriosis there is a very compromised bone quality 
with lower trabecular volume, fewer trabeculae number, 
higher trabecular interruption and cortical porosity than 
in controls as evaluated by HR-pQCT (101, 102, 103). 
The fracture incidence in patients with breast cancer 
treated with aromatase inhibitors was 7-26% at 7  years 
of treatment (104), and about 23-28% in patients with 
prostate cancer on antiandrogen therapy (105). Overall 
the fractures occur very precociously after the start of 
hormonal ablation, when BMD is often not impaired 
(104, 106). The increased awareness about CTIBL has 
led to guidelines and expert panel to recommend to 
monitor for bone loss with BMD by DXA (107). However 
in a retrospective study on 17,110 breast cancer survivor 
followed about 5 years demonstrated that the increased 
risk of a fracture was not explained by worse BMD 
suggesting that BMD does not adequately capture bone 
strength determinants as shown in other studies (108). 
When postmenopausal women with breast cancer treated 
with aromatase inhibitors were randomised to receive 
placebo or denosumab, the risk of all fracture in placebo 
group and the risk of fracture reduction in denosumab 
group were substantially independent of BMD (104). 
Interestingly, in patients with prostate cancer the fracture 
risk is better expressed by calculating FRAX without BMD 
than with BMD (109).
In keeping with the idea that that skeletal fragility 
is prominently dependent on the poor quality of bone 
microarchitecture, in In patients with breast cancer treated 
with exemestane, TBS significantly decreases of 2.3% and 
BMD of 5% in 24 months of treatment and in particular 
the changes were independent from each other (110). In a 
retrospective longitudinal study in breast cancer patients 
treated with aromatase inhibitors for more than 3 years, 
along with an impairment of bone quality parameters, TBS 
also significantly decreased from baseline to 5 years (2.1%) 
and this change remained significant after adjusting for 
LS BMD (111). In B-ABLE study TBS and BMD significantly 
decreased in not treated patients with breast cancer, while 
in bisphosphonates treated subjects BMD increased and 
TBS remained stable at the end of the treatment with 
aromatase inhibitors. In both groups the changes in 
spine BMD and TBS were weakly correlated (112). Similar 
results were found in premenopausal breast cancer 
women treated with zoledronic acid (113). Therefore, TBS 
could be suitable to improve the fracture risk definition 
in CTIBL patients and could be usefully combined with 
FRAX and BMD to maximise the identification of patients 
with elevated risk (114).
In the future, other technologies that capture a 
combination of bone mass and bone quality and the 
possibility to assess the separate role of trabecular and 
cortical bone could potentially be useful for fracture 
risk definition in CTIBL besides DXA. Indeed, MRI of 
trabecular microarchitecture actually refers to imaging 
of the marrow contents of the trabecular bone tissue 
compartment. These studies were performed with 1.5T, 
3T and 7T MRI. Cortical bone is an important contributor 
to bone strength as evidenced by recent data using MRI. 
Cortical bone has a very short T2 relaxation times (<1 ms) 
and, using a very short or ultra-short echo, cortical bone 
porosity and collagen-bound water could be captured. The 
available in vivo clinical studies are so far very few (115).
 In patients with prostate cancer on androgen 
deprivation therapy, with vertebral fracture MRI 
demonstrated bone quality deterioration at distal 
radius compared to controls and the addition of these 
parameters to BMD significantly improves the ability 
to individuate fractured patients (115). Even pQCT is 
available method to quantify separately cortical and 
trabecular bone at peripheral skeletal site. In breast 
cancer patients on hormonal adjuvant therapy pQCT 
surprisingly demonstrated a prominent negative impact 
of anastrozole on cortical bone as compared with healthy 
control women (104).
Recently also ancillary analyses of PET-CT examinations 
were compared against values obtained using routine 
multidetector-row computed tomography (MDCT) with 
promising performances (116). However, to date, there are 
not strong evidences that microarchitecture definition by 
MRI, MDCT or QCT could become the standard methods 
to assess the risk of fractures in hypogonadal subjects. It is 
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likely that a combination of different technologies should 
offer the best definition of bone strength but also the cost-
effectiveness of this approach should be determined.
Fracture risk assessment in 
secondary osteoporosis
In many conditions other than postmenopausal 
osteoporosis the fracture risk is neglected or 
underestimated and the use of an algorithm represents 
the solution to ensure a homogeneous evaluation among 
specialists and an appropriate approach to therapy. The 
most commonly used is FRAX® that calculates absolute 
fracture probability from ten easily obtained risk factors 
in optional conjunction with BMD T-score values (117). 
Among the risk factors ‘secondary osteoporosis’ is 
included, which encompasses namely: type 1 diabetes, 
osteogenesis imperfecta in adults, untreated long-
standing hyperthyroidism, hypogonadism or premature 
menopause (before 45  years), chronic malnutrition and 
chronic liver disease. Many other well-known conditions 
associated to bone fragility, such as hyperparathyroidism, 
T2DM, obesity, cancer and hormonal adjuvant therapy, 
HIV, chronic inflammatory bowel disease and obstructive 
respiratory disease are not included (https://www.
sheffield.ac.uk/FRAX, last access 02.12.2019), although 
they have been very recently re-evaluated (118).
Endogenous hypercortisolism is not formally included 
but the term ‘glucocorticoid’ is among the ten risk factors 
and in the place of the term ‘obesity’ the term ‘BMI’ is 
present. Moreover, FRAX calculation has been included in 
some International Guidelines as IOF/ECTS, ESCEO and 
American College of Rheumatology for the management 
of glucocorticoid osteoporosis and CITBL in breast and 
prostate cancer (119, 120, 121).
 However, FRAX has been designed to assess fracture 
risk in postmenopausal osteoporosis which substantially 
differs as compared with the condition of bone fragility due 
to endocrine disorders. Indeed, in these latter conditions, 
bone microarchitecture alterations and/or other factors 
(as for example the risk of fall) are crucial determinant 
of the fracture risk. Therefore, in these condition the 
DXA values may substantially underestimate the risk of 
fracture (4, 43, 84, 85, 122, 123). This explains why in 
these condition the ‘secondary osteoporosis’ option in the 
FRAX tool has a much smaller effect on fracture risk than 
would be expected, and it has been suggested to use the 
bypass of rheumatoid arthritis in the FRAX tool to correct 
the estimation of fracture risk (122). Moreover, since BMD 
in many conditions is not impaired or it is even higher 
than expected (4, 43, 84, 85, 122, 123), the fracture risk 
prediction by FRAX may be improved by excluding BMD 
in the algorithm computation (4, 124, 125, 126) or by 
downward adjusting BMD by 0.5 standard deviation (39). 
Finally the TBS-adjusted FRAX, being TBS an independent 
fracture risk capturing ‘quality’ aspects of bone structure, 
has suggested to possibly improve the absolute fracture 
risk definition in secondary osteoporosis (114, 127, 128).
In conclusion for the absolute fracture risk 
assessment in the majority of secondary osteoporosis 
FRAX is currently not performing as in postmenopausal 
osteoporosis and the ‘secondary osteoporosis’ option does 
not adequately correct the underestimation of the fracture 
risk. Excluding BMD, or including ‘Arthritis Rheumatism’ 
or TBS could currently be options to improve the fracture 
risk predictability using FRAX in secondary osteoporosis. 
As suggest in the update of the European Guidelines for 
osteoporosis imminent new FRAX version could be take 
in account these needs for the management of secondary 
osteoporosis (118).
Conclusions and perspectives
In the present review we have summarised the available 
data about the imaging tools that can be used in evaluating 
the fracture risk in patients with the most common 
endocrine forms of osteoporosis and bone fragility. A 
summary of the main characteristics of the different non-
invasive imaging methods for the assessment of bone 
health is reported in Table 4.
It is possible, however, that even in healthy subjects, 
the endocrine milieu (in term of degree of secretion, 
peripheral activation and sensitivity) could play a 
role in predisposing to fracture risk. Indeed, cortisol 
levels seems to be associated with BMD in women with 
postmenopausal osteoporosis (129, 130), the activity of 
the 11β-hydroxysteroid dehydrogenase shuttle, which 
regulates the glucocorticoid peripheral activity, seems to 
influence the risk of vertebral fractures (131, 132), and the 
different GC receptor polymorphisms, have been suggested 
to be associated with the fracture risk in patients with no 
evidence of cortisol excess (133, 134). Furthermore, recent 
data show that even in primary aldosteronism femur and 
spine BMD and TBS are reduced (135, 136) and that the 
fracture risk is increased (137, 138). This clinical picture 
as well as fracture risk recedes after treatment, particularly 
after surgery (139). Since aldosterone secretion is increased 
in a large part of hypertensive patients (139), altogether 
Downloaded from Bioscientifica.com at 12/02/2020 10:33:24AM
















180:6 R226Review C Eller-Vainicher and others Imaging in endocrine 
osteoporosis
https://eje.bioscientifica.com
these data may suggest that cortisol and aldosterone 
secretion may represent two so far ignored contributors to 
osteoporosis in the general population.
The issue of hypovitaminosis D and of secondary 
hyperparathyroidism as possible endocrine causes of 
bone fragility was beyond the scope of the present review. 
However, it is important to underline that hypovitaminosis 
may be a potential contributor to bone fragility in all 
forms of secondary osteoporosis and may influence 
their diagnostic work-up. Indeed in up to 30% of cases, 
the diagnosis of PHPT may be missed if the biochemical 
work-up is performed in the presence of low vitamin D 
levels (2). Besides hypovitaminosis D, a concomitant 
mineralisation disorder, impacting on bone density and 
quality could influence the effect of an endocrine disease 
on bone fragility (140, 141). Therefore, in all endocrine-
related forms of bone fragility, the vitamin D status has to 
be assessed and the presence of a mineralisation disorder 
has to be excluded.
Finally, a limit of many studies assessing bone 
fragility in the endocrine disorders is related to the 
clinical significance of morphometric vertebral fractures. 
Indeed, in all studies cited in the presence review the 
morphometric vertebral fractures were defined as at 
least a 20% deformity (i.e. at least I grade). However, the 
significance and predictive ability of grade I vertebral 
fractures for future fractures is still questioned (142).
In conclusion, the endocrine-related forms of 
osteoporosis are characterised by an increased risk of 
fracture, which is often hardly predictable by DXA. Even 
though TBS seems to be useful for assessing the fracture 
risk in patients affect with an endocrine disease, further 
studies are needed. In particular, TBS is incapable of directly 
assessing osseous microarchitecture and the overall effect 





Clinical and research applications Disadvantages
DXA Areal BMD Lumbar spine, hip, 
radius, total body
WHO diagnosis of osteoporosis, 
input for FRAX, body 
composition evaluation
2D nature, lack of compartment-
specific BMD measurement
TBS Pixel grey-level 
texture 
Lumbar spine Index of trabecular bone 
quality, improvement of 
FRAX prediction
Not useful for monitoring 
treatment response
VFA Vertebral fractures Thoracolumbar 
spine 
Detection of vertebral fractures 
by using DXA image 
(sensitivity and specificity 
>90% for moderate and 
severe fractures)
Low sensitivity for detecting mild 
vertebral fractures









Detection of morphometric 
vertebral fractures, SDI 
calculation
Low sensitivity for diagnosing low 
BMD
QUS SOS, BUA and 
other derived 
parameters 
Heel, phalanges of 
the non-dominant 
hand
Indirect quantification of bone 
tissue properties and BMD 
without ionising radiation 
exposure
High rate of change of QUS 
parameters, not to be used for 
diagnosing osteoporosis, for 
monitoring treatment 
response and with FRAX
QCT-based 
methods
Volumetric BMD Distal radius, tibia 
(HR-pQCT)
Spine (central QCT)
Assessment of cortical and 
trabecular bone 
compartments, QCT-derived 
FEA modelling for bone 
strength estimation
High costs, low availability, 
ionising radiation exposure. 








Assessment of bone 
microarchitecture, MRI-
derived FEA modelling for 
bone strength estimation 
(HR-MRI)
BMF evaluation (MRS)
High costs, low availability. For 
research purposes only
BMD, bone mineral density; BMF, bone marrow fat; BUA, broadband ultrasound attenuation; DXA, dual-X-ray absorptiometry; FEA, finite element 
analysis; HR-MRI, high-resolution magnetic resonance imaging; HR-pQCT, high-resolution peripheral quantitative computed tomography; HSA, hip 
structural analysis (DXA-based method); MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; QCT, quantitative computed 
tomography; QUS, quantitative ultrasound; SDI, spinal deformity index; SOS, ultrasound speed of sound; TBS, trabecular bone score (DXA-based 
measurement); VFA, vertebral fracture assessment (DXA-based method).
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of the joint use of TBS with FRAX is modest, with most of 
its clinical impact limited to patients already close to an 
intervention threshold. Moreover, in some studies TBS did 
not improve ROC curves on fracture risk over femur BMD 
alone. Finally, to date, we have no sufficient evidence 
suggesting that TBS can be used to assess the effect of 
pharmacologic anti-fracture treatment (143).
Hopefully, in the future, new imaging methods 
for evaluating both bone density and quality could be 
introduced in the clinical practice. This would help to 
better identify patients with endocrine diseases at high 
risk of fracture, therefore consenting their early treatment. 
These methods could even consent to evaluate the effect 
of the drug therapy and medical rehabilitation on the 
skeletal health in patients affected with an endocrine-
related form of bone fragility.
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